本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Tarsus Pharmaceuticals, Inc.

68.81
-0.1500-0.22%
盤後68.810.00000.00%17:53 EDT
成交量:52.40萬
成交額:3,639.13萬
市值:29.05億
市盈率:-29.75
高:70.84
開:68.72
低:68.70
收:68.96
52周最高:76.81
52周最低:38.51
股本:4,221.41萬
流通股本:3,035.16萬
量比:1.21
換手率:1.73%
股息:- -
股息率:- -
每股收益(TTM):-2.3129
每股收益(LYR):-3.0729
淨資產收益率:-31.46%
總資產收益率:-14.06%
市淨率:8.73
市盈率(LYR):-22.39

資料載入中...

2025/03/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/18

重要事件披露

Form 8-K - Current report
2025/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/13

重要事件披露

Form 8-K - Current report
2025/02/25

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/02/25

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/25

重要事件披露

Form 8-K - Current report
2025/01/17

重要事件披露

Form 8-K - Current report
2025/01/13

重要事件披露

Form 8-K - Current report
2024/12/19

重要事件披露

Form 8-K - Current report
2024/11/14

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]